Latest & greatest articles for Famciclovir

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Famciclovir or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Famciclovir and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Famciclovir

1. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. (PubMed)

Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Recurrent genital herpes simplex virus (HSV) may be treated episodically, but this may not be sufficient for patients with frequent recurrences.To determine the efficacy and safety of famciclovir in the suppression of recurrent genital HSV infection.A randomized, double-blind, placebo-controlled, parallel-group study.Thirty university (...) , hospital, or private outpatient referral centers in Canada and Europe.A total of 455 patients (223 men, 232 women) aged 18 years or older with a history of 6 or more episodes of genital herpes during 12 of the most recent 24 months, in the absence of suppressive therapy, received study medication.Oral famciclovir, 125 mg or 250 mg 3 times daily or 250 mg twice daily, or placebo for 52 weeks.Time to the first recurrence of genital HSV infection; the proportion of patients remaining free of HSV

1998 JAMA Controlled trial quality: predicted high

2. Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia

Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia Huse D M, Schainbaum S, Kirsch A J, Tyring S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Famciclovir therapy for reducing the duration of post-herpetic neuralgia (PHN). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Immunocompetent adults with uncomplicated herpes zoster, diagnosed within 72 hours of onset of rash. Setting Primary care centres in the US, Canada and Australia. Dates to which data relate

1997 NHS Economic Evaluation Database.

3. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. (PubMed)

Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. To compare the efficacy and safety of episodic patient-initiated oral famciclovir with placebo in recurrent genital herpes.Randomized, double-blind, frequent-observation, dose-ranging study comparing twice-daily 125-mg, 250-mg, or 500-mg oral famciclovir with placebo. Patients initiated therapy after self-culturing, reported (...) of lesion edema, vesicles, ulcers, and crusts. Times to cessation of all symptoms and of moderate to severe lesion tenderness, pain, and burning were also reduced. Patients who initiated famciclovir prior to viral shedding were more likely to not shed virus throughout. All doses were equally effective, safe, and well tolerated.Oral famciclovir reduced the onset and duration of viral shedding, lesion persistence, and uncomfortable symptoms. Several individual symptoms and lesion stages were also reduced

1996 JAMA Controlled trial quality: predicted high